glp-1 receptor agonists alternatives to ozempic PDB-101: Molecule of the Month: From cheaper injectables to oral
Description
Diab Res
The SURMOUNT-1 trial for tirzepatide showed average weight loss of 15 to 22 percent of body weight across the full study population
Mazdutide has demonstrated remarkably low discontinuation rates (near 1% in early trials) compared to retatrutide (12-18% in Phase 3)
The TECOS trial showed no difference between the placebo and a sitagliptin group (Table 2) [47,48,49]
